In 2023, the sales of beta-blocking medication in Canada were experiencing stable growth. However, from 2024 onwards, forecasts indicate a minor decline, with the sales value per capita dropping slightly from 2024's $5.2 to $5 by 2026 and stabilizing through 2028. Year-on-year, the market shows a decreasing trend: a -1.92% drop in 2025, followed by a -1.96% decrease in 2026, with sales stabilizing thereafter. The compound annual growth rate (CAGR) highlights a minimal decline during the forecast period.

Future trends to watch: